'Maybe a little antacid, in the form of more M&A, could help us fight through the pain.'
The point that acquisitive firms must keep in mind is that risks must be taken to achieve future growth. Buying a shot on goal, or two, for a couple of billion dollars may offer better return on risk than either pouring money into internal research or taking on a big debt load to pay for a megamerger.SEE ALSO: Local pharma firm’s IPO ‘couldn’t come at a worse time’
Georgia-based HealtPort, which has a small local presence in former Symbion executive Billy Webb, has filed an S-1 with the Securities & Exchange Commission. Webb was previously the chief development officer and a director with ambulatory surgery center operator Symbion. He left the company in 2007 to join HealthPort.